Lars G Weiss

Learn More
BACKGROUND Novel peritoneal dialysis solutions are characterized by a minimal content of glucose degradation products and a neutral pH. Many studies have shown the biocompatibility of neutral lactate-buffered solutions; however, until now, the effect of purely bicarbonate-buffered solutions has not been intensively studied in vivo. METHODS This study was(More)
Chronic renal insufficiency is characterized by specific abnormalities in lipoprotein metabolism, affecting both apolipoprotein A (apo A)- and apo B-containing lipoproteins. To evaluate the effects of fluvastatin, a synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on renal dyslipoproteinemia, we performed a randomized, double-blind,(More)
We investigated whether renal function and microalbuminuria are independent predictors and whether any interaction exists between them, regarding future cardiovascular disease in hypertensive patients (n=10 881) followed for 4.5 years. The primary end points (PEs) were fatal and nonfatal myocardial infarction and stroke and other cardiovascular deaths.(More)
  • Lars G Weiss
  • Nephrology, dialysis, transplantation : official…
  • 2001
The availability of recombinant human erythropoietin (rh-Epo) has revolutionized the treatment of renal anaemia. Subcutaneous (s.c.) administration of rh-Epo offers significant advantages over the intravenous (i.v.) route, and numerous studies have demonstrated its efficacy and tolerability when administered two or three times weekly. Most of these studies(More)
We investigated whether renal function and microalbuminuria are independent predictors and whether any interaction exists between them, regarding future cardiovascular disease in hypertensive patients (n 10 881) followed for 4.5 years. The primary end points (PEs) were fatal and nonfatal myocardial infarction and stroke and other cardiovascular deaths.(More)
  • Lars G Weiss
  • Nephrology, dialysis, transplantation : official…
  • 2002
Epoetin administration once weekly to renal failure patients is not new, and indeed a series of publications examining this frequency of administration appeared in the early 1990s [1–11]. During the last decade, however, nephrologists largely settled on twiceor thrice-weekly administration for most of their patients, and the small number who end up on(More)
  • Lars G Weiss
  • Nephrology, dialysis, transplantation : official…
  • 2002
The efficacy and safety of intravenous (i.v.) and subcutaneous recombinant human erythropoietin (rh-EPO, epoetin) for the treatment of renal anaemia is well established. Subcutaneous administration of epoetin is recommended by current guidelines because it is more flexible and convenient than i.v. dosing, enables dose reduction of epoetin and results in(More)